Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody

Journal article

Peer reviewed

Alexander J. Rossi, Tahsin M. Khan, Areeba Saif, Thomas U. Marron and Jonathan M. Hernandez

Annals of surgical oncology, Vol.29(1), pp.30-32

01/01/2022

DOI: 10.1245/s10434-021-10269-7

PMID: 34117573

View Online

no abstract

Oncology

Surgery

Life Sciences & Biomedicine

Science & Technology

Title: Subtitle: Treatment of Hepatocellular Carcinoma with Neoadjuvant Nivolumab Alone Versus in Combination with a CCR2/5 Inhibitor or an Anti-IL-8 Antibody
Creators: Alexander J. Rossi - National Institutes of Health
Tahsin M. Khan - National Institutes of Health
Areeba Saif - National Institutes of Health
Thomas U. Marron - Icahn School of Medicine at Mount Sinai
Jonathan M. Hernandez - National Institutes of Health
Resource Type: Journal article
Publication Details: Annals of surgical oncology, Vol.29(1), pp.30-32
DOI: 10.1245/s10434-021-10269-7
PMID: 34117573
NLM abbreviation: Ann Surg Oncol
ISSN: 1068-9265
eISSN: 1534-4681
Publisher: Springer Nature
Number of pages: 3
Grant note: ZIABC011861 / National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
Language: English
Date published: 01/01/2022
Academic Unit: Surgery
Record Identifier: 9985224322002771

2 Record Views